The Patent Finder

Terms ending in 2043

Ono Pharmaceutical Co., Ltd.

Every in-force patent on Ono Pharmaceutical Co., Ltd.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,122,846Chimeric Antigen Receptor for Tumor Targeting
In force
 · High confidence
Fate Therapeutics, Inc.In forceHigh confidence
US 12,630,510EP2 Antagonist
In force
 · High confidence
Ono Pharmaceutical Co., Ltd.In forceHigh confidence
US 12,698,286Compound Having KDM5 Inhibitory Activity and Pharmaceutical Use Thereof
In force
 · High confidence
Ono Pharmaceutical Co., Ltd.In forceHigh confidence
US 12,630,544NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF
In force
 · High confidence
National Institutes for Quantum Science and Technology, Eisai R&D Management Co., Ltd., Ono Pharmaceutcal Co., Ltd. and Takeda Pharmaceutical Company LimitedIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Ono Pharmaceutical Co., Ltd..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited